A new study published in Nature suggests that with a cellular and molecular map of the healthy human heart, experts may be able to better understand what goes wrong in cardiovascular disease.

Anthos Therapeutics is developing next-generation anticoagulants that do not have the bleeding risks that current blood thinners have.

Novartis boss Vas Narasimhan expects higher sales and profitability for 2020, lifted by the company’s broad range of medicines, and minimal disruption to the Swiss drugmaker’s supply chain from the coronavirus outbreak in China.

Amarin Corporation plc announced the launch of True To Your Heart, an educational campaign to help people learn more about cardiovascular disease and how to better protect against persistent cardiovascular risk.

First-time marathon runners can add years to their lives and reap the health rewards of lower blood pressure and healthier arteries, even if they take on the challenge in mid-to-later life, research showed.

Sanofi is ending diabetes and cardiovascular (DCV) research efforts as part of a revamp to narrow the number of the company’s business units in the hope of bolstering growth and profit.

Amgen filed a Worker Adjustment and Retraining in California with plans to cut 172 jobs at the company’s headquarters and U.S. field operations effective December 31, 2019.

A panel of experts to the U.S. FDA recommended allowing Amarin Corp. Plc’s fish-oil derived drug to be used as an add-on therapy for reducing the chance of heart attacks and strokes in high-risk patients with cardiovascular disease.

Bayer and biotechnology company Dewpoint Therapeutics announced an option, research and license agreement worth up to $100 million.

The U.S. FDA approved Janssen’s Xarelto (rivaroxaban) for preventing blood clots in acutely sick patients in hospitals who are at risk for blood clots but who are not at high risk of bleeding.